论文部分内容阅读
近年来,心血管药物的研发似乎进入了瓶颈期,一些备受瞩目的试验均以失败告终。制药业利润的不断下降是否应归咎于研发效率的低下?
In recent years, the research and development of cardiovascular drugs seems to have entered a bottleneck, and some highly-anticipated experiments have failed. Should the declining profitability of the pharmaceutical industry be attributed to the low efficiency of R & D?